Physician profile
William B Roth
NPI 1215934187
$16,830.73
in general payments reported to CMS, 2019-2025
36 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 76% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,284 · 2020: $1,850 · 2021: $1,563 · 2022: $4,416 · 2023: $4,201 · 2024: $1,811 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,286 · Travel and Lodging: $2,392 · Education: $38.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,286.40 |
| Travel and Lodging | $2,392.37 |
| Education | $38.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $3,662.03 | 2021-2024 | Axonics, Bulkamid |
| Coloplast Corp | $3,558.80 | 2019-2025 | Titan |
| Teleflex LLC | $2,376.94 | 2021-2025 | Urolift, Barrigel |
| Medtronic, INC. | $1,542.61 | 2021-2022 | |
| Neotract INC. | $1,437.78 | 2019-2020 | |
| Astellas Pharma US INC | $811.37 | 2019-2025 | Xtandi, Myrbetriq |
| Abbvie INC. | $624.08 | 2019-2025 | Botox, Lupron Depot |
| Endo USA, INC. | $432.39 | 2024-2025 | Xiaflex, Aveed |
| Boston Scientific Corporation | $342.21 | 2019-2025 | Ams 800 Artificial Urinary Sphincter |
| Calyxo, INC. | $265.15 | 2025 | Cvac Aspiration System |
| Allergan, INC. | $239.78 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $215.30 | 2019-2024 | Xiaflex |
| Antares Pharma, INC. | $213.55 | 2019-2023 | Tlando, Nocdurna, Xyosted |
| Pfizer INC. | $157.38 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $120.87 | 2020-2025 | Provenge |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $120.31 | 2023 | Orgovyx, Gemtesa |
| Myovant Sciences INC. | $118.22 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $70.21 | 2019-2025 | Adstiladrin |
| Janssen Biotech, INC. | $66.25 | 2019-2025 | Erleada |
| Tolmar, INC. | $53.29 | 2023 | |
| Laborie Medical Technologies Corp. | $53.00 | 2025 | |
| Zyla Life Sciences, INC. | $48.69 | 2019 | |
| Blue Earth Diagnostics | $44.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $38.84 | 2020-2024 | Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $35.11 | 2019-2022 | |
| Dentsply Ih INC. | $28.18 | 2019 | |
| Cardiovascular Systems INC. | $27.21 | 2019 | |
| Medtronic USA, INC. | $24.69 | 2019-2020 | |
| Travere Therapeutics, INC. | $21.62 | 2021 | |
| Accord Healthcare, INC. | $20.41 | 2022 | |
| Ethicon US, LLC | $13.58 | 2019 | |
| Intuitive Surgical, INC. | $12.95 | 2020 | |
| Clarus Therapeutics INC. | $12.03 | 2021 | |
| Urogen Pharma, INC. | $11.31 | 2021 | |
| Civco Medical Instruments | $10.29 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.